Grepafloxacinの体液内濃度測定法の検討

• 向井 典江

  大塚製薬株式会社微生物研究所

• 大森 和則

  大塚製薬株式会社微生物研究所

• 玉岡 寿

  大塚製薬株式会社微生物研究所

• 菊地 幹雄

  大塚製薬株式会社微生物研究所

• 秋山 仁

  大塚製薬株式会社徳島研究所

• 小富 正昭

  大塚製薬株式会社徳島研究所

書誌事項

タイトル別名

• Methods for the bioassay and high-performance liquid chromatography of grepafloxacin in body fluids

抄録

A microbiological assay procedure and high-performance liquid-chromatography (HPLC) procedure have been developed for determining grepafloxacin (GPFX) in human plasma and urine.<BR>In the bioassay method drug concentrations were determined by the thin-layer cup method, using Bacillus subtilis ATCC6633 as the test strain and nutrient agar as the test medium. Calibration curves of GPFX were made in human plasma and 1/15M phosphate buffer (P. B.) pH 7.4 for plasma samples and in 1/15M P. B. pH 7.0 for urine samples. The lowest detectable concentration of GPFX by the method was 0.012-0.025 μg/ml.<BR>In HPLC GPFX was extracted from plasma and urine by chloroform. The extracts were analyzed using a reverse-phase analytical column and detected by the fluorescence method. The intra-assay coefficient of variation for plasma was less than 4.6% at 0.01-1.00, μg/ml and less than 3.5% at 0.025-5.00 μg/ml, whereas for diluted urine it was less than 4.0% at 0.25-50.00 μg/ml. Plasma and urine samples in phase I studies were analyzed by HPLC and the bioassay method. A good corelation was observed between them.

収録刊行物

• 日本化学療法学会雑誌

  日本化学療法学会雑誌 43 (Supplement1), 91-98, 1995

  公益社団法人 日本化学療法学会

キーワード

• キノロン薬
• bioassay法
• HPLC法

詳細情報

• CRID: 1390001206287244160
• NII論文ID: 10005465914
• NII書誌ID: AN10472127
• DOI: 10.11250/chemotherapy1995.43.supplement1_91
• ISSN: 18845886
• ISSN: 13407007
• Web Site: https://search.jamas.or.jp/link/ui/1996000980
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可